Search Medical Condition
Please enter condition
Please choose location
 

Esplugues de Llobregat (Barc), Spain Clinical Trials

A listing of Esplugues de Llobregat (Barc), Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (716) clinical trials

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to <18 years will be enrolled, of which at least 30 will be ...

Phase

0.0 miles

Learn More »

A Clinical Trial to Assess the Effect of HC-SVT-1001 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones

The purpose os this study is to evaluate the safety and effectiveness of HC-SVT-1001 in the surgical treatment of atrophic nonunion in long bones.

Phase

0.0 miles

Learn More »

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability

Phase

0.0 miles

Learn More »

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

0.0 miles

Learn More »

A Study of Safety Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Each subject will undergo a screening period of up to 5 weeks, a treatment period of 2 weeks with PK sample collection, and an extension treatment period of 48 weeks, to allow subjects access to apremilast treatment if medically appropriate (following the completion of the 2 week PK portion). Regardless ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia

This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).

Phase

0.0 miles

Learn More »

-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

This two-part open-label study will assess 2 different canakinumab taper regimens in patients with clinical remission (inactive disease for at least 24 continuous weeks) on canakinumab treatment without concomitant corticosteroids (CS) or methotrexate (MTX). The study will also collect long term safety and tolerability data on SJIA patients treated with ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Efficacy and Safety of REGN2222 for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

This study occurs in two parts: Part A and Part B. The status of Part A is 'Complete'. The status of Part B is 'Recruiting.' Part A of the study is an open-label, PK evaluation of intramuscular (IM) administered REGN2222 in preterm infants for whom palivizumab is not recommended to ...

Phase

0.0 miles

Learn More »

Multicenter Single-arm Study to Evaluate Efficacy Safety & Pharmacokinetics of Denosumab in Children w/ OI

To evaluate the effect of denosumab on lumbar spine bone mineral density(BMD) Z-score at 12 months, as assessed by dual-energy X-ray absorptiometry (DXA), inchildren 2 to 17 years of age with osteogenesis imperfecta.

Phase

0.0 miles

Learn More »

CD19 CART Long Term Follow Up (LTFU) Study

Patients are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CD19 directed CAR T-Cell treatment and will be followed for 15 years post treatment from the last CD19 directed CAR T-Cell treatment. Patients will be monitored for safety and efficacy within the primary treatment ...

Phase N/A

0.0 miles

Learn More »